Migraine

2024

Russian company released headphones to cure mental disorders

On April 19, 2024, the Russian company Neiry, together with the National Medical Research Center of PN named after V.M. Bekhtereva, presented Neiry Buds headphones that can be used for the therapy of mental disorders. It is claimed that the gadget helps in the treatment of conditions such as insomnia, anxiety, stress, migraines and various pain sensations. Read more here.

Migraine implantable device released

On February 6, 2024, the American medical device developer ShiraTronics introduced an implantable migraine treatment device in the head. The system uses neurostimulation technology to eliminate the debilitating symptoms of this ailment. Read more here.

2023

1% increase in sales of migraine drugs to 8 million packages

At the end of 2023, approximately 8 million packages of migraine drugs were sold in Russia. This is 1% more compared to the previous year, when sales were estimated at 7.9 million units. At the same time, in monetary terms, the market volume increased by 10% - from 2.7 billion rubles to 3 billion rubles. Such data are given in the AlphaRM study, the results of which were published on February 7, 2024.

According to Pharmvestnik, in 2023 the average price of packaging a migraine drug rose by 8% on an annualized basis. For comparison: in 2022, the increase in relation to the previous year was 18%, and in 2021 - about 17%. This is partly due to the appearance on the Russian market of expensive drugs for headaches (monoclonal antibodies).

𝓲

AlphaRM

The study says that in 2023, eight INNs (international non-proprietary name) from migraines presented by 23 brands were sold on the Russian market. The dominant position among them is occupied by sumatriptan - it accounts for about 76% in rubles and 92% in packages in the corresponding segment of the retail market. Sales of drugs with sumatriptan in monetary terms in 2023 increased by 6.3% compared to the previous year. There are nine brands on the Russian market offering drugs with this active ingredient.

Erenumab is in second place in the ranking of the best-selling migraine drugs in Russia, which accounted for approximately 7.6% in monetary terms in 2023. Eletriptan closes the top three with a share of about 7.3% in money. The top five also include zolmitriptan and fremanezumab with results of 5% and 3.4%, respectively. By the end of 2023, the share of all other drugs, including risatriptan (a new drug), was less than 0.5% for each.^[1]

Russian pharmacists have developed and registered a new medicine for migraine

The Russian pharmacists developed and registered a migraine drug. This was Rusnano reported on March 21, 2023.

The drug "Relonova" of the company "NovaMedica" is designed to stop headache in case of migraine attacks. Read more here.

2022: Release of a new version of the migraine treatment device, for which $45 million was raised

In late August 2022, Theranica announced serial sales of an updated shoulder-worn migraine treatment device. For the wide commercial implementation of the project, the manufacturer attracted $45 million in investments. Read more here.

2021

Initiation of the use of the K.O.S. neuromodulation system for the treatment of chronic migraine

At the end of May 2021, the Swedish medical technology company Chordate Medical developed and patented a new neuromodulation technology for the treatment and prevention of chronic migraine in adult patients. The development was called K.O.S. More details here.

Reliion Announcement - Neuromodulation Systems for Migraine Treatment

In early March 2021, the company Neurolief introduced a non-invasive neuromodulation system Relivion for the treatment of migraine. This multichannel brain neuromodulation system brain is designed to treat acute migraine at home, taking into account the individual characteristics of the patient. The system completely stops the symptoms of migraine within 2 hours of application. More. here

Notes